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less costly than UFH. These ﬁndings were robust with
respect to changes in the background risk of throm-
boembolism and risk of death from competing causes.
CONCLUSIONS: Thromboprophylaxis with enoxaparin
represents a cost-effective use of health-care resources and
dominates strategies involving the use of UFH in acutely-
ill medical inpatients.
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TOTAL DIRECT MEDICAL AND DRUG COSTS
OF NON-ADHERENCE TO STATIN THERAPY
WITHIN THE FIRST YEAR OF TREATMENT
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OBJECTIVE: Controlled trials have demonstrated the
positive impact of statins on health outcomes in hyper-
lipidemic patients. However, few studies analyzed the
cost-effectiveness of adherence to statins. 
METHODS: Data were retrospectively gathered from a
commercial, integrated pharmacy/medical claims data-
base. Patients over 18 years with at least two statin
claims, a 120-day beneﬁt history, and a 360-day contin-
uous enrollment were selected for inclusion. Age, gender,
and concomitant drug/disease information were collected.
Adherence to statins was calculated as (total days sup-
plied)/(last claim date—ﬁrst claim date + last days
supply)*100. Total medical and drug costs, (TMDC),
including drug, hospital, physician visit and lab informa-
tion, were used to calculate per-member-per-month
(PMPM) costs during the follow-up period. Number of
patients and days to institutionalization for a disease-
related event (DRE) was determined and the costs for
DRE were calculated. ANOVA, or a non-parametric
equivalent, was used to test results across adherence 
quintiles.
RESULTS: 2317 patients (62% male) were included in
this analysis. The mean sample age was 53 with patients
taking an average of 7.1 medications concomitantly.
72.8% of patients were less than 80% adherent and
nearly 1/3 were less than 39% adherent. The median
TMDC for the sample was $379 PMPM, with costs sig-
niﬁcantly decreasing as adherence decreased (P < 0.0001).
The median cost for DRE was $313 PMPM, and also
decreased as adherence decreased, except for the >100%
adherent patients whose costs were less than the median,
though not signiﬁcantly (P = 0.703). Adherence was not
signiﬁcant in affecting the days to DRE (P = 0.4559). 
CONCLUSION: Although statins reduce cardiovascular
events over multiple years, this study conﬁrms that cost
savings cannot be expected in the ﬁrst year. If drug costs
are included in the total costs, one cannot expect an
increase in adherence to decrease the total direct health
care costs in the ﬁrst year of treatment.
PCV16
DIFFERENCES IN HOSPITAL LENGTH-OF-STAY,
CHARGES AND MORTALITY IN CONGESTIVE
HEART FAILURE PATIENTS
Joshi AV1, D’Souza AO2, Madhavan SS3
1West Virginia University/Pﬁzer, Morgantown, WV, USA;
2West Virginia University/Aventis, Morgantown, WV, USA;
3West Virginia University, Morgantown, WV, USA
OBJECTIVE: To demonstrate differences in hospital
length-of-stay (LOS), charges, and mortality in CHF
patients by hospital and patient characteristics using 
the 1997 Hospital Cost and Utilization Project (HCUP)
database. 
METHODS: Hospitalizations with ICD-9-CM codes for
CHF were extracted from a 10% random HCUP sample
to yield 19,746 hospitalizations representing 22 states.
Hospital variables included region (Northeast, Midwest,
South, West), location (urban/rural), teaching/non-
teaching status, ownership (government, for-proﬁt, not
for-proﬁt), and hospital size (small, medium, large).
Patient variables included age (< = 50 years, 51–65 years,
>65 years), race (white, African-American, others),
gender, income (<$25,000, $25,000–$30,000, $30,000–
$35,000, >$35,000), number of comorbidities, and payer
status (Medicare, Medicaid, private/HMO, self-pay).
One-way ANOVA and chi-square statistics were used to
test for signiﬁcant (p < = 0.05) differences.
RESULTS: On average, CHF patients incurred charges of
$11,866 per hospitalization. The mean LOS per hospi-
talization was 5.83 days and the in-hospital mortality was
4.6 percent. LOS and hospital charges increased with
disease severity when patients were classiﬁed into 3 sever-
ity levels based on the number of comorbidities. Self-pay
patients had the longest LOS (8.69 days) but the lowest
charges ($11,418), and privately-insured/HMO patients
had the shortest LOS (5.33 days) but the highest charges
($13,381). For-proﬁt hospitals reported the highest mean
charges, followed by private/not proﬁt and government
hospitals. Mortality did not vary by region, location,
ownership and teaching status. Elderly patients (>65) 
had signiﬁcantly higher charges as compared to younger
patients (<50) ($ 13,817 vs. $11,607) and had higher
mortality (5.4% vs. 1.6%). High-income patients
incurred signiﬁcantly higher charges as compared to 
low-income patients ($13,456 vs. $10,840). Whites had
higher mortality (5.1%) as compared with others (4.6%)
and African-Americans (2.8%). LOS and charges did not
vary by race or gender. 
CONCLUSION: Hospital LOS, charges and mortality in
CHF patients show marked differences when compared
by patient and hospital characteristics.
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OBJECTIVES: To assess, from a societal perspective, 
the cost-effectiveness of use of ramipril (Altace®) after
invasive revascularization, based on the Angiotensin-
converting Enzyme Inhibition Post Revascularization
Study (APRES), which found that ramipril was associated
with signiﬁcantly reduced risk of cardiac mortality and of
non-fatal events. 
METHODS: Probabilities of acute myocardial infarction
(AMI), congestive heart failure (CHF), angina pectoris
and cardiac mortality associated with ramipril or placebo
from APRES, a randomized, double-blind, placebo-
controlled study of 159 patients who had undergone
revascularization were applied to a decision-analytic
model. Reduction in risk of non-fatal events was used to
model expected costs and reduction in risk of cardiac
mortality was used to deﬁne effectiveness. Unit costs were
based on hospitalization charges from the 1997 Health-
care Cost and Utilization Project (HCUP-3), adjusted 
by the Medicare cost-to-charge ratio, as well as costs
obtained from published literature. Drug costs were 
based on published average wholesale prices (AWP) from
the 1997 Red Book. All costs were discounted at 3% per
year.
RESULTS: Based on average daily AWP of $0.94,
ramipril was associated with a discounted incremental
cost of $934 per patient over 33 months of treatment and,
after accounting for cost offsets due to reduced risk of
clinical events, a net expected incremental cost per patient
of $327. Given a 7.6% absolute risk reduction in cardiac
mortality (8.9% less 1.3%, p < 0.05), ramipril was asso-
ciated with an incremental expected cost of $4,300 per
death averted and, correspondingly, $371 per life year
saved, based on additional life expectancy in this patient
population. Sensitivity analysis indicated that these esti-
mates ranged from a total cost offset (minus $61 per life
year saved) in the best scenario to $861 per life year saved
in the worst scenario.
CONCLUSIONS: Ramipril is expected to be a cost-
effective addition to medical management of patients
undergoing revascularization.
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SOCIETY AND THE ASSOCIATION WITH BODY
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Overweight and obesity are seen to be major risk factors
for costly chronic diseases and can worsen other chronic
conditions, leading to important health care resources
absorption. There is evidence that health care resources
use is associated with the severity of obesity expressed as
body mass index (BMI).
OBJECTIVES: To examine direct and indirect costs per
overweight and obese subject and to investigate the asso-
ciation between BMI and the costs of caring for over-
weight and obese subjects.
METHODS: The ﬁrst 10 overweight and obese subjects
attending 52 medical ofﬁces in Italy were enrolled.
Medical and economic information was retrospectively
collected using an electronic questionnaire. The societal
perspective was adopted. Costs considered were direct
(visits, diagnostics, drugs, other therapies, hospitalisa-
tions) and indirect (working activity reduction or
abandon) and refer to a 6-month period. The association
of costs with BMI was explored using parametric and non
parametric tests as appropriate. All costs are in Euro year
2001 (1 Euro = 0.9 US$).
RESULTS: The mean age of the 367 subjects enrolled was
43.18 (±12.9) and the mean BMI 35.34 (±6.72). 73.6%
of the subjects were females, and 77.7% obese (BMI >
30). The mean 6-months health-care cost estimated was
855 Euro per subject. Hospitalisation was the health-care
cost driver (64% of the total), followed by drugs (7%),
visits and diagnostics (6% each). 16% percent of the
sample reduced working activity by 35% on average. The
cost of care for an overweight subject was signiﬁcantly
lower compared to an obese (685 vs. 917 Euro, P =
0.011). BMI was associated with direct costs (P = 0.004)
and with work abandon or reduction (p = 0.001). 
CONCLUSIONS: The present study gives the opportu-
nity to understand how health care expenditure vary
across a wide range of BMI values in Italy and this could
have important implications for targeting preventive and
weight reduction interventions.
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Studies show that aspirin is very effective as secondary
prevention of cardiovascular events, however its use for
primary prevention of cardiovascular disease (CVD) is
questionable. There are clinical trials performed to study
its effectiveness for primary prevention, however cost-
effectiveness studies have not been done to see the trade-
off between decreased CVD and increased adverse events.
OBJECTIVES: Primarily, this paper seeks to calculate 
the incremental cost-effectiveness ratios (ICERs) of using
aspirin in males and females aged 40–80 with no prior
history of CVD. Secondarily, to calculate the ICERs of
HMG-CoA Reductase Inhibitors compared to aspirin. 
METHODS: The cost-effectiveness ratios were calculated
for a hypothetical cohort of patients using a decision 
analytic spreadsheet model with a societal perspective in
2001 U.S. Dollars. Measurements of costs, effectiveness,
utilities, and rates of events were obtained from literature.
A series of one-way sensitivity analyses were performed 
to test the robustness of the model. For the secondary
objective, the incremental costs and incremental CVD risk
reduction obtained from using HMG-CoA Reductase
Inhibitors instead of aspirin is applied to the model to
